Predicting benefit from anti-angiogenic agents in malignancy

  title={Predicting benefit from anti-angiogenic agents in malignancy},
  author={Adrian M. Jubb and Adam J. Oates and Scott Holden and Hartmut Koeppen},
  journal={Nature Reviews Cancer},
A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second… CONTINUE READING